Parity and disability progression in relapsing-remitting multiple sclerosis

被引:12
|
作者
Achiron, Anat [1 ]
Ben-David, Alon [2 ]
Gurevich, Michael [1 ]
Magalashvili, David [1 ]
Menascu, Shay [1 ]
Dolev, Mark [1 ]
Stern, Yael [1 ]
Ziv-Baran, Tomer [3 ]
机构
[1] Tel Aviv Univ, Multiple Sclerosis Ctr, Sheba Med Ctr, Sackler Sch Med, Tel Aviv, Israel
[2] Tel Aviv Univ, Sheba Med Ctr, Sackler Sch Med, Dept Obstet & Gynecol, Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Tel Aviv, Israel
关键词
Relapsing-remitting multiple sclerosis; Pregnancy; Parity; Disability progression; Immunomodulatory treatment; DIAGNOSTIC-CRITERIA; PREGNANCY; ONSET; GUIDELINES; PREDICTORS;
D O I
10.1007/s00415-020-10093-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aim It is unclear whether parity and increasing parity are risk factors for long-term disability progression in relapsing-remitting multiple sclerosis. Furthermore, data on the effects of immunomodulatory treatments in this context are limited. Objectives To examine the association between parity and long-term neurological sequela among relapsing-remitting multiple sclerosis patients. Methods A cohort study including all women with relapsing-remitting multiple sclerosis in Israel registered in Sheba Medical Center Multiple Sclerosis data registry from 1995 to 2018. The risks of progression to moderate and severe disability according to parity after disease onset were evaluated. Cox regression models using childbirth as a time-dependent covariate were used to study the association between parity and disability progression. Results During the 26,785 person-years of follow-up a total of 2281 women were included in the study. Parity was associated with decreased risk of progression to moderate (adj.HR, 0.68; 95% CI 0.54-0.85,P = 0.001) but not to severe disability (adj.HR, 0.88; 95% CI 0.68-1.14,P = 0.36). Hazard ratios for progression to moderate and severe disability were comparable between women with one, two, and three or more births. In a subgroup analysis of women who gave birth within 5 years of disease onset, immunomodulatory treatment did not affect moderate or severe disability-free survival. Conclusion This study suggests that childbirth after the onset of multiple sclerosis is associated with a decreased risk of progression to moderate neurological disability.
引用
收藏
页码:3753 / 3762
页数:10
相关论文
共 50 条
  • [31] Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis
    Achiron, A
    Barak, Y
    Rotstein, Z
    [J]. MULTIPLE SCLEROSIS, 2003, 9 (05): : 486 - 491
  • [32] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Zhou, Hongyu
    Han, Wenjie
    Zhang, Shihong
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
  • [33] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    [J]. NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [34] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [35] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [36] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [37] Baseline cognitive function is predictive of clinical disability progression in relapsing-remitting multiple sclerosis: a statistical approach
    Pellegrini, F.
    Xiao, J.
    Castrillo, C.
    Raghupathi, K.
    Pace, A.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E315 - E315
  • [38] Flexible modeling of disease activity measures improved prognosis of disability progression in relapsing-remitting multiple sclerosis
    Le Teuff, Gwenael
    Abrahamowicz, Michal
    Wynant, Willy
    Binquet, Christine
    Moreau, Thibault
    Quantin, Catherine
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2015, 68 (03) : 307 - 316
  • [39] Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab
    Dekker, I
    Leurs, C. E.
    Hagens, M. H. J.
    van Kempen, Z. L. E.
    Kleerekooper, I
    Lissenberg-Witte, B., I
    Barkhof, F.
    Uitdehaag, B. M. J.
    Balk, L. J.
    Wattjes, M. P.
    Killestein, J.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 82 - 87
  • [40] Natalizumab arrests cortical atrophy progression in relapsing-remitting multiple sclerosis
    Rinaldi, F.
    Calabrese, M.
    Mattisi, I.
    Seppi, D.
    Puthenparampil, M.
    Perini, P.
    Gallo, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S195 - S196